647863-25-0

Basic information

• Product Name: tert-Butyl 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate
• Synonyms: tert-Butyl 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate;tert-butyl 4-(2,2,2-trifluoroacetyl)-3-oxopiperidine-1-carboxylate;1-Boc-3-oxo-4-(2,2,2-trifluoroacetyl)piperidine;tert-butyl 3-oxo-4-(trifluoroacetyl)piperidine-1-carboxylate
• CAS NO: 647863-25-0
• Molecular Formula: C₁₂H₁₆F₃NO₄
• Molecular Weight: 295.2549496
• Mol File: 647863-25-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-Butyl 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate(647863-25-0)
• EPA Substance Registry System: tert-Butyl 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate(647863-25-0)

Safety Data

• Hazardous Substances Data: 647863-25-0(Hazardous Substances Data)

Usage

General Description

Tert-butyl 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate is a synthetic compound with a complex chemical structure. It contains a tert-butyl group, a piperidine ring, and a trifluoroacetyl group. tert-Butyl 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate is commonly used in organic synthesis and medicinal chemistry as a building block for the creation of other chemical compounds. The presence of the trifluoroacetyl group makes this compound particularly useful for introducing fluorine atoms into organic molecules, which can have significant effects on their properties. It is important to handle this chemical with care, as it may pose potential risks if not used properly.

Upstream product

• 647863-23-8 tert-butyl 5-[(trimethylsilyl)oxy]-3,4-dihydropyridine-1(2H)-carboxylate 
• 647863-24-9 tert-butyl 5-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 407-25-0 trifluoroacetic anhydride 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 733757-89-6 6-tert-butoxycarbonyl-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine 
• 647863-27-2 tert-butyl 2-(4-chlorophenyl)-4-(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidine-7 (6H)-carboxylate 
• 911635-51-3 t-butyl 2-cyclopropyl-4-(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate 
• 911636-87-8 tert-butyl 2,4-bis(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-7-carboxylate 
• 853784-47-1 2-methyl-3-trifluoromethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine 
• 794451-98-2 1-methyl-3-trifluoromethyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine 
• 853784-23-3 3-trifluoromethyl-4,5,6,7-tetrahydro-isoxazolo[3,4-c]pyridine 
• 1022930-40-0 1-({4-[6-methyl-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl]phenyl}methyl)-2-pyrrolidinone 

Relevant articles and documents

Integration of lead optimization with crystallography for a membrane-bound ion channel target: Discovery of a new class of AMPA receptor positive allosteric modulators

A novel series of AMPAR positive modulators is described that were identified by high throughput screening. The molecules of the series have been optimized from a high quality starting point hit to afford excellent developability, tolerability, and effica

DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE AGENT

Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.

COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE

Compound of formula (I) and salts thereof are provided: wherein A, R1, R, R2 are as defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.